Prima BioMed (IMMP)
(Real Time Quote from BATS)
$1.89 USD
+0.02 (1.07%)
Updated Aug 8, 2024 03:14 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Prima BioMed Ltd falls in the month of June.
All items in Millions except Per Share data.
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 83 | 58 | 45 | 18 |
Receivables | NA | 5 | 6 | 5 | 2 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 2 | 2 | 1 | 1 |
Total Current Assets | NA | 91 | 66 | 51 | 21 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 6 | 8 | 10 | 10 |
Deposits & Other Assets | NA | 2 | 0 | 0 | 0 |
Total Assets | NA | 99 | 74 | 61 | 31 |
Liabilities & Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 6 | 4 | 4 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 7 | 5 | 4 | 2 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 1 | 1 | 2 | 6 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 1 | 1 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 7 | 6 | 7 | 9 |
Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 300 | 267 | 234 | 163 |
Capital Surplus | NA | 0 | 0 | 0 | 0 |
Retained Earnings | NA | -229 | -219 | -205 | -185 |
Other Equity | NA | 20 | 21 | 26 | 44 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 92 | 68 | 55 | 22 |
Total Liabilities & Shareholder's Equity | NA | 99 | 74 | 61 | 31 |
Total Common Equity | 0 | 92 | 68 | 55 | 22 |
Shares Outstanding | 118.80 | 87.90 | 86.60 | 76.20 | 48.70 |
Book Value Per Share | 0.00 | 1.05 | 0.79 | 0.72 | 0.46 |
Fiscal Year End for Prima BioMed Ltd falls in the month of June.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,931 | -99,999 | 83 |
Receivables | NA | NA | 4 | NA | 5 |
Notes Receivable | NA | NA | NA | NA | 0 |
Inventories | NA | NA | NA | NA | 0 |
Other Current Assets | NA | NA | 2 | NA | 2 |
Total Current Assets | NA | NA | 74 | NA | 91 |
Net Property & Equipment | NA | NA | 0 | NA | 0 |
Investments & Advances | NA | NA | NA | NA | 0 |
Other Non-Current Assets | NA | NA | NA | NA | 0 |
Deferred Charges | NA | NA | NA | NA | 0 |
Intangibles | NA | NA | 6 | NA | 6 |
Deposits & Other Assets | NA | NA | 1 | NA | 2 |
Total Assets | NA | NA | 81 | NA | 99 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | NA | 0 |
Accounts Payable | NA | NA | 4 | NA | 6 |
Current Portion Long-Term Debt | NA | NA | NA | NA | 0 |
Current Portion Capital Leases | NA | NA | NA | NA | 0 |
Accrued Expenses | NA | NA | NA | NA | 0 |
Income Taxes Payable | NA | NA | NA | NA | 0 |
Other Current Liabilities | NA | NA | 0 | NA | 0 |
Total Current Liabilities | NA | NA | 4 | NA | 7 |
Mortgages | NA | NA | NA | NA | 0 |
Deferred Taxes/Income | NA | NA | NA | NA | 0 |
Convertible Debt | NA | NA | 1 | NA | 1 |
Long-Term Debt | NA | NA | NA | NA | 0 |
Non-Current Capital Leases | NA | NA | NA | NA | 0 |
Other Non-Current Liabilities | NA | 0 | NA | 0 | |
Minority Interest (Liabilities) | NA | NA | NA | NA | 0 |
Total Liabilities | NA | NA | 5 | NA | 7 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | NA | 0 |
Common Stock (Par) | NA | NA | 291 | NA | 300 |
Capital Surplus | NA | NA | NA | NA | 0 |
Retained Earnings | NA | NA | -235 | NA | -229 |
Other Equity | NA | NA | 20 | NA | 20 |
Treasury Stock | NA | NA | NA | NA | 0 |
Total Shareholder's Equity | NA | NA | 75 | NA | 92 |
Total Liabilities & Shareholder's Equity | NA | NA | 81 | NA | 99 |
Total Common Equity | 0 | 0 | 100,074 | 0 | 92 |
Shares Outstanding | 118.80 | 118.80 | 118.80 | 87.90 | 87.90 |
Book Value Per Share | 0.00 | 0.00 | 842.38 | 0.00 | 1.05 |